logo
Share SHARE
FONT-SIZE Plus   Neg

Appeals Court Says Rituxan, Avastin Do Not Infringe Sanofi Patents

An appeals court on Thursday upheld a lower court's ruling that the cancer drugs Rituxan and Avastin of Swiss drug maker Roche Holding AG's (RHHBY.PK) Genentech unit and biotechnology firm Biogen Idec Inc. (BIIB) do not infringe two patents of French drug maker Sanofi SA (SNY,SNYNF.PK).

Genentech's Avastin, which had sales of 5.29 billion Swiss francs in 2011, is a blockbuster drug for treatment of cancers related to colon, lung, kidney and brain. Rituxan had sales of 6.01 billion Swiss francs in 2011. Rituxan is currently co-marketed by Biogen Idec and Genentech in the U.S.

In a ruling posted on the court's website, the U.S. Court of Appeals for the Federal Circuit said that Sanofi's '522 and '140 patents were not infringed by Genentech and Biogen. The court ruled that the district court had not erred in its judgment.

In October 2008, Sanofi filed a lawsuit for infringement of the two patents, alleging that Genentech and Biogen made use of an infringing enhancer in producing the antibody-based drugs Rituxan and Avastin.

SNY closed Thursday's trading at $38.45, down $0.23 or 0.59 percent on a volume of 1.86 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dutch consumer electronics giant Philips Electronics NV Wednesday announced a definitive merger agreement to buy Spectranetics Corp., a vascular intervention and lead management solutions provider. Under the deal, Philips will commence a tender offer to buy Spectranetics for $38.50 per share, to be paid in cash upon completion. The implied enterprise value is approximately 1.9 billion euros. Samsung Electronics Co. is reviving its Galaxy Note 7 premium smartphone, which was recalled last year over faulty battery issues. A refurbished version of the smartphone with different components under the name Galaxy Note 7 Fandom Edition or FE will be coming to retailers' shelves on July 7, reports said. A massive cyberattack has hit Europe on Tuesday, spreading to U.S. and Asia, affecting businesses and government systems with ransom demands. The new ransomware attack, in a possible reprise of a widespread WannaCry assault in May, is said to be caused by the virus linked to malware called Petrwrap or Petya. The affected users are told to pay $300 in cryptocurrency per infected computer...
comments powered by Disqus
Follow RTT